Results 111 to 120 of about 4,266 (228)

Managing delayed union of fragility fractures of the pelvis successfully using romosozumab: A case report

Trauma Case Reports
Fragility fractures of the pelvis (FFPs) are typically caused by minor trauma or without any trauma in older individuals with osteoporosis. In recent years, FFP incidence has increased considerably owing to the increasing number of individuals in the ...
K. Wada, A. Tominaga, M. Naruo, K. Okazaki   +3 more
doaj   +1 more source

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

Post hoc analysis of FRAME and ARCH revealed that on-study nonvertebral and vertebral fractures by Month 12 were less common in women initially treated with romosozumab versus placebo or alendronate.
Kurth, A., Oates, Mary, Timoshanko, J., Stone, Michael, Libanati, Cesar, Lane, joseph, Langdahl, Bente, Cosman, Felicia, Wang, Zhenxun   +8 more
core   +1 more source

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab

, 2017
Most current treatments for osteoporosis inhibit bone resorption and reduce total fracture numbers by about one-quarter. The identification of the osteocytic protein sclerostin as a potent regulator of bone turnover and bone density has led to the ...
Reid, Ian, Ian R. Reid
core   +1 more source

Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment

International audienceRomosozumab treatment results in a transient early increase in bone formation and sustained decrease in bone resorption. Histomorphometric analyses revealed that the primary bone-forming effect of romosozumab is a transient early ...
Chapurlat, Roland, Betah, Donald, Oates, Mary, Eriksen, Erik, Chavassieux, Pascale, Boyce, Rogely, Brown, Jacques, Libanati, Cesar, Shi, Yifei   +8 more
core   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Examining Romosozumab Adherence and Side Effects in Osteoporotic Patients After Surgical Fracture Fixation: A Comparative, Descriptive, and Hypothesis-Generating Study with Non-Fractured Controls

Diseases
Objectives: The study aims to evaluate adherence to Romosozumab treatment in osteoporotic patients after surgical fracture fixation and compare side effects with non-fractured controls on the same therapy.
Amarildo Smakaj, Umberto Tarantino, Riccardo Iundusi, Angela Chiavoghilefu, Lorenzo Abbondante, Chiara Salvati, Chiara Greggi, Elena Gasbarra   +7 more
doaj   +1 more source

A practical approach for anabolic treatment of bone fragility with romosozumab

Background: Romosozumab, a fully humanized anti-sclerostin-antibody, is a bone-builder stimulating osteoblasts and inhibiting osteoclast by activation of the canonical Wnt-beta catenin signaling.
Mazziotti, G., Cianferotti, L, Palermo, A, Zavatta, G., Mazziotti, G, Palermo, A., Cianferotti, L., Cipriani, C., Cipriani, C, Viapiana, O., Viapiana, O, Zavatta, G   +11 more
core   +1 more source

Rationale and study design of a randomized controlled trial to investigate the effect of romosozumab on bone mineral density in hemodialysis patients with osteoporosis (the TRINITY study): A study protocol

Renal Replacement Therapy
Background Dialysis patients are at a high risk of fracture; however, little evidence is currently available regarding optimal treatment strategies. Romosozumab is a new drug for osteoporosis that promotes bone formation and inhibits bone resorption ...
Toshihiro Mizukoshi, Yachiyo Kuwatsuka, Masahiko Ando, Nobuhiro Nishibori, Hirotake Kasuga, Masato Tsuboi, Shoichi Maruyama, Sawako Kato   +7 more
doaj   +1 more source

Effects of romosozumab combined with routine therapy on pain relief, disease progression and adverse reactions in patients with postmenopausal osteoporosis: a systematic review and meta-analysis

Frontiers in Medicine
BackgroundPostmenopausal osteoporosis (PMOP) increases fracture risk in women. Though traditional treatments are slow to act, combining romosozumab with conventional therapy shows promise.
Ge Gao, Jian Cui, Yuanyuan Xie, Jing Dong   +3 more
doaj   +1 more source